queenie digital circus

The Apprentice star also argued that a lack of clarity from the Government on the ownership test is causing “significant uncertainty” for potential investors. This came as the House of Lords continued its scrutiny of the Football Governance Bill, which seeks to establish an independent regulator for the top five tiers of the men’s game. In the upper chamber, Baroness Brady said: “We are creating legislation which will profoundly affect 160 quite unique institutions, from Premier League clubs through to the National League community clubs, but it is important for everyone to understand that the consultation with these affected businesses by the current Government has been remarkably limited, almost unbelievably so. “Just seven Premier League clubs, I was one of them, was granted a brief half-hour meeting with the Secretary of State over the summer. “And following this cursory engagement, significant decisions were made that could fundamentally affect the future of English football, most notably with the inclusion of parachute payments within the backstop mechanism. “This is particularly concerning given that fundamental issues still remained unresolved, we still lack any clarity on Uefa’s position on state interference, for example, this clearly creates profound uncertainty for clubs competing in or aspiring to European competition, as well as our national teams.” “We don’t know what the ownership test will look like, this causes significant uncertainty for potential investors as to whether they are able to own a club,” she added. Lady Brady continued: “I have spoken to many of my colleagues across all of the football pyramid, we are all alarmed about and puzzled by the lack of discussion on the Bill with ministers. “Would the minister agree that we all want to get the detail of this Bill right? And can she see any downsides to providing meaningful opportunities to hear from all clubs across the football pyramid affected by the legislation?” Prior to this, Tory shadow sports minister Lord Parkinson of Whitley Bay had tabled an amendment which he said would allow clubs to “make their views known on this legislation” by including specific competitions on the face of the Bill. Labour frontbencher Baroness Twycross told the upper chamber: “I don’t think the leagues are confused either on which leagues this legislation will apply to.” She added: “This power is both reasonable and the result of evidence-based consultation with all key stakeholders in the industry. “This power ensures that the competitions in scope can be amended in a timely manner and ensures the scope of the regime remains relevant.” The peer later said: “Over the past three years there have been countless opportunities for all affected and interested parties to make representations.” Lady Brady also raised concerns about the financial distribution backstop, which she said is “clearly designed as a mechanism to gain direct access to, and apportionate Premier League revenue, and no-one else’s”. “I might add the backstop will allow the IFR (Independent Football Regulator) to do this even if it was against the Premier League clubs’ will, or even without the clubs’ agreement, even if it was to have a detrimental effect on the clubs and the overall competition it removes revenue from,” she added. The backstop would allow the new IFR to intervene in the distribution of Premier League broadcast revenue down the leagues as a last resort. It could be triggered by the Premier League, English Football League (EFL) or National League to mediate the fair financial distribution of this revenue if they are not able to come to an agreement. Conservative peers later raised concerns over the cost implications to clubs of establishing the regulator, although they faced claims of “filibustering” – wasting time by making overlong speeches in a bid to delay progress. Labour peer Lord Watson of Invergowrie questioned why Lord Parkinson was showing “confected outrage” at the Bill when the former culture minister would have been defending a similar proposal had the Tories remained in power. Lord Parkinson, in his reply, said: “We want to see this regulator established, we want to see it doing its work and doing so effectively, but we also see before us a Bill that is different because of the election that was called and the result that happened, and we’re interrogating particularly closely the changes that the Government have made to the Bill – of which there are many. “And we have more concerns on these benches than we did before the election from my colleagues behind me about the way we do it.” The Tory peer pointed to Labour frontbenchers fulfilling their duties to “properly scrutinise” then-government legislation when they were on the opposition benches. Lady Twycross, in an intervention, said: “While I agree that (Lord Parkinson) is correct that I would scrutinise legislation when I was sitting on those (opposition) benches, I have never sought to filibuster a Bill to which my party had committed, which my party had laid before Parliament, and intended to filibuster it to the point of getting us stuck in treacle.” Lord Parkinson replied: “That is not what we’re doing.” Niall Couper, chief executive of the campaign group Fair Game, wrote on social media site X: “Watching opposition benches blatantly filibustering to destroy the Football Governance Bill is nothing short of sporting vandalism.”queenie digital circus 。

Keratoconus Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, Clinical Trials by DelveInsight | CooperVision, Optik Seis, SAFILENS S.R.L, Novartis, CIBA VISION, Menicon, Bausch & Lomb 11-25-2024 08:31 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Keratoconus pipeline constitutes 3+ key companies continuously working towards developing 3+ Keratoconus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Keratoconus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Keratoconus Market. The Keratoconus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Keratoconus Pipeline Report: https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Keratoconus treatment therapies with a considerable amount of success over the years. •Keratoconus companies working in the treatment market are Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others, are developing therapies for the Keratoconus treatment •Emerging Keratoconus therapies in the different phases of clinical trials are- Riboflavin 5'-Phosphate, IVMED-80, Dextenza, and others are expected to have a significant impact on the Keratoconus market in the coming years. •In October 2024, Glaukos Corporation (NYSE: GKOS), a pharmaceutical and medical technology company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, announced positive results from the second Phase 3 confirmatory pivotal trial for EpioxaTM (Epi-on). This next-generation corneal cross-linking iLink therapy for keratoconus met its pre-specified primary efficacy endpoint, showing a clinically meaningful and statistically significant improvement in maximum corneal curvature (Kmax) at 12 months compared to the sham/placebo-controlled group. Kmax, an FDA-accepted primary efficacy metric for keratoconus trials, measures the steepest corneal curvature using topography, with higher Kmax values indicating corneal steepening and disease progression. Keratoconus Overview Keratoconus is a progressive eye disease in which the normally round, dome-shaped cornea thins and begins to bulge into a cone-like shape. This cone shape deflects light as it enters the eye, causing distorted vision. Get a Free Sample PDF Report to know more about Keratoconus Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/keratoconus-pipeline-insight Emerging Keratoconus Drugs Under Different Phases of Clinical Development Include: •Riboflavin 5'-Phosphate: Glaukos Corporation •IVMED-80: iVeena Delivery Systems •Dextenza: Ocular Therapeutix, Inc. Keratoconus Route of Administration Keratoconus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Keratoconus Molecule Type Keratoconus Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Keratoconus Pipeline Therapeutics Assessment •Keratoconus Assessment by Product Type •Keratoconus By Stage and Product Type •Keratoconus Assessment by Route of Administration •Keratoconus By Stage and Route of Administration •Keratoconus Assessment by Molecule Type •Keratoconus by Stage and Molecule Type DelveInsight's Keratoconus Report covers around 3v+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Keratoconus product details are provided in the report. Download the Keratoconus pipeline report to learn more about the emerging Keratoconus therapies https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Keratoconus Therapeutics Market include: Key companies developing therapies for Keratoconus are - CooperVision, Optik Seis, SAFILENS S.R.L, Novartis AG, CIBA VISION, Menicon Co. Ltd, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care Inc, HOYA Vision Care, and others. Keratoconus Pipeline Analysis: The Keratoconus pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Keratoconus with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Keratoconus Treatment. •Keratoconus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Keratoconus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Keratoconus market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Keratoconus drugs and therapies https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Keratoconus Pipeline Market Strengths •Environmental factors contribute to the wide variation in prevalence. Geographical locations with plenty of sunshine and hot weather have a higher prevalence than locations with colder climates and less sunlight Keratoconus Pipeline Market Opportunities •There is limited approved therapy for Keratoconus, which opens up a huge platform of new therapies to boon the market. Scope of Keratoconus Pipeline Drug Insight •Coverage: Global •Key Keratoconus Companies: Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix, Inc., and others •Key Keratoconus Therapies: Riboflavin 5'-Phosphate, IVMED-80, Dextenza, and others •Keratoconus Therapeutic Assessment: Keratoconus current marketed and Keratoconus emerging therapies •Keratoconus Market Dynamics: Keratoconus market drivers and Keratoconus market barriers Request for Sample PDF Report for Keratoconus Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/keratoconus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Keratoconus Report Introduction 2. Keratoconus Executive Summary 3. Keratoconus Overview 4. Keratoconus- Analytical Perspective In-depth Commercial Assessment 5. Keratoconus Pipeline Therapeutics 6. Keratoconus Late Stage Products (Phase II/III) 7. Keratoconus Mid Stage Products (Phase II) 8. Keratoconus Early Stage Products (Phase I) 9. Keratoconus Preclinical Stage Products 10. Keratoconus Therapeutics Assessment 11. Keratoconus Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Keratoconus Key Companies 14. Keratoconus Key Products 15. Keratoconus Unmet Needs 16 . Keratoconus Market Drivers and Barriers 17. Keratoconus Future Perspectives and Conclusion 18. Keratoconus Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Keratoconus Market https://www.delveinsight.com/report-store/keratoconus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Keratoconus Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Keratoconus Epidemiology https://www.delveinsight.com/report-store/keratoconus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Keratoconus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports Offered By DelveInsight: •Structural Heart Devices Market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market •Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market •Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market •Cardiac Arrythmia Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market •Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market •Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.Sunday, 4:25 p.m. EST, FOX BetMGM NFL odds: Chargers by 3. Against the spread: Buccaneers 8-5; Chargers 9-4. Series record: Chargers lead 8-4. Last meeting: Chargers beat Buccaneers 38-31 in Tampa, Fla., on Oct. 4, 2020. Last week: Buccaneers beat Las Vegas 28-13; Chargers lost to Kansas City 19-17. Buccaneers offense: overall (3), rush (8), pass (6), scoring (5). Buccaneers defense: overall (28), rush (11), pass (30), scoring (22). Chargers offense: overall (24), rush (19), pass (25), scoring (13). Chargers defense: overall (11), rush (T-14), pass (8), scoring (1). Turnover differential: Buccaneers minus-2; Chargers plus-11. QB Baker Mayfield is trying to lead Tampa Bay to a fourth consecutive NFC South title. He’s already matched a career-best for touchdown passes with 28, but also hasn’t done as good a job of taking care of the football as a year ago. He threw for 295 yards and three TDs in last week’s 15-point win over Las Vegas. He also turned the ball over three times in the first half to help the Raiders stay close until the fourth quarter. WR Quentin Johnston bounced back from a couple of tough performances to make five catches for 48 yards and a touchdown against the Chiefs. But inconsistency has been the defining trait of the slow start to Johnston’s NFL career, so being able to follow it up will be telling. The Chargers needed the 2023 first-round pick to step up with rookie Ladd McConkey sidelined because of knee and shoulder injuries last week. With McConkey's status to play Sunday uncertain, Johnston could be called on again. Chargers RB Kimani Vidal vs. Buccaneers LB Lavonte David. Vidal, a rookie from Troy, seems to have increased his standing in the Chargers’ backfield that definitely missed J.K. Dobbins (knee). Vidal had eight carries for 34 yards while playing 53% of the offensive snaps in Kansas City, more than starter Gus Edwards. The Chargers are going to stick to the run under coach Jim Harbaugh, which means the newcomer Vidal will have to outfox a 13-season veteran in David. At 34, David remains a force, making seven tackles, a sack, a tackle for loss and recovering a fumble against the Raiders. He is eight tackles away from his 11th season of triple-digit stops. Bucs S Antoine Winfield Jr. left last week’s game with a knee sprain and is expected to be sidelined a couple of weeks. Leading rusher Bucky Irving has a back injury that will be evaluated as the week progresses. ... Chargers QB Justin Herbert is dealing with a sprained left ankle, but doesn't believe it is as serious as the right high ankle sprain he sustained in Week 2 against Carolina. Herbert was able to play through that ailment, which should bode well for his availability. While the Chargers won eight of the first nine meetings between the franchises, Tampa Bay took the past three. ... This will be the Buccaneers’ third trip to Los Angeles and second to SoFi Stadium, where they lost 34-24 to the Rams in September 2021. The Bucs are 7-1 in December/January regular-season games going back to last season. They’re 19-5 in those games going back to 2020, the first of Tom Brady’s three years with Tampa Bay. ... WR Mike Evans needs 17 receptions and 426 yards over the next four games to finish with his 11th consecutive season with at least 60 catches and 1,000 yards receiving. ... Evans had seven receptions for 122 yards and a TD the previous time Tampa Bay faced the Chargers (Oct. 4, 2020). ... The Bucs have rushed for 100-plus yards in 10 of 13 games. That’s after doing it just nine times over 34 games the past two regular seasons. ... With leading rusher Bucky Irving sitting out most of last week’s game against Las Vegas with a back injury, starter Rachaad White took up the slack with 90 yards rushing on 17 attempts — both season highs. He also scored two TDs, one receiving. ... White’s rushing TD was the 14th for Tampa Bay. That’s more than the Bucs scored on the ground in 2022 (five) and 2023 (eight) combined. ... The Chargers have turned the ball over a league-low six times. The franchise record for fewest giveaways in a season is 15, which they did in 2006 and 2017. ... Herbert hasn’t thrown an interception in 11 straight games. That is tied with Brady for the longest streak in NFL history. Brady closed out the 2010 regular season for New England without being picked off after Week 5. ... S Derwin James Jr. has three tackles for loss and two sacks in his past three games. ... PK Cameron Dicker has made 65 of 66 field goals under 50 yards in his career, with his 98.5% success rate the best in league history. Dicker has made all 30 attempts inside of 50 yards at home. ... The Chargers defense allowed 17 of 31 third down conversions (54.8%) in two games against the Chiefs. They have held their other 11 opponents to 45 of 146 (30.8%). The Buccaneers find ways to play shootouts, with eight of their games seeing the winner score 30 or more points. The Chargers find ways to play grinding affairs, with only two of their games seeing the winner score 28 or more points. Whoever dictates the style of play will determine how much fantasy value comes out of this game. AP NFL: https://apnews.com/hub/NFL

Metro movers

Purdy not throwing during 49ers practice, limited to handoffsCeltic manager Brendan Rodgers praised Cameron Carter-Vickers and his side’s mentality after they dug out a Champions League point following the defender’s disastrous own goal against Club Brugge. The normally reliable centre-back passed the ball into his own net in the 26th minute after failing to spot goalkeeper Kasper Schmeichel’s positioning. But a brilliant turn and finish on the hour mark from Daizen Maeda changed the game and ultimately earned the Scottish champions a 1-1 home draw. On the opener, Rodgers said: “Mistakes happen and it was just unfortunate. He’s played that pass a million times and it’s gone back and then we’ve been able to play forward. It was just one of those unfortunate moments in the game that happens. “But he’s a really, really tough character. He’s a great guy, he picked himself up. He was really strong and aggressive again in the game and got on with it and had a real bravery in the second half, because he was the one carrying the ball forward for us to start the attack.” Despite the gift, Brugge were worthy of their lead and Rodgers admitted his side were too passive in their pressing in the opening half. Some tactical tweaks – and the introduction of Paulo Bernardo – helped Celtic dominate after Maeda’s equaliser, although Brugge had a goal disallowed for a marginal offside. “I can only credit the players for the second half, because we had to fight,” Rodgers said. “And we’re still one of those teams that’s really pushing to try and make a mark at this level. So to make the comeback, score the goal, play with that courage, I was so pleased. “You want to win but I’ve been here enough times to have lost a game like that, but we didn’t. We showed a real strong mentality and we kept pushing right to the very end and the players did well. “I thought they showed great courage in the second half because we weren’t at our level in the first half. Sometimes a game like that can get away from you, but it didn’t. “We stayed with it, showed that determination, showed that mentality, never to quit, to keep going. And then we were much, much better, much freer in the second half. “So we’re on eight points, nine to play for. We’re still very much on course to get to where we want to get to and still three games to go.” Rodgers added: “It’s 20 games now and we’ve won 16 and drawn three and lost one, so it shows you the mentality is there, and especially at this level, you need to have that.”

Pet passports for dogs, cats and ferrets to travel within UK ‘an outrage’